Background The rate and degree of LDL cholesterol reduction, in the first 2 weeks of
therapy, may relate to the early benefit of hydroxymethyl glutaryl coenzyme A reductase …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

This double-blind study to evaluate long-term efficacy and safety of atorvastatin was
performed in 31 community-and university-based research centers in the USA to directly …

Lowering of serum cholesterol levels by pharmacologic intervention with statins reduces the
incidence of cardiovascular events in subjects with and without atherosclerotic …

BACKGROUND: The NASDAC study was designed to evaluate the safety and efficacy of
atorvastatin at starting doses of 10, 20, 40, and 80 mg. METHODS: After an 8-week placebo …

The efficacy and safety of atorvastatin 10 mg versus simvastatin 20 mg and atorvastatin 80
mg versus simvastatin 80 mg was determined in a 6-week, prospective, randomized, open …

Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …

Background Previous trials have demonstrated that lowering low-density lipoprotein (LDL)
cholesterol levels below currently recommended levels is beneficial in patients with acute …

This randomized, placebo-controlled, double-masked, parallel-group trial assessed the
serum cholesterol—lowering effects of atorvastatin, a new 3-hydroxy-3-methylglutaryl …